Cash Equivalents - Intercept Pharmaceuticals Inc (F:I4P) - Alpha Spread
I

Intercept Pharmaceuticals Inc
F:I4P

Watchlist Manager
Intercept Pharmaceuticals Inc
F:I4P
Watchlist
Price: 17.52 EUR Market Closed
Market Cap: 732.8m EUR
Have any thoughts about
Intercept Pharmaceuticals Inc?
Write Note

Intercept Pharmaceuticals Inc
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Intercept Pharmaceuticals Inc
Cash Equivalents Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
I
Intercept Pharmaceuticals Inc
F:I4P
Cash Equivalents
$102.7m
CAGR 3-Years
31%
CAGR 5-Years
12%
CAGR 10-Years
12%
Abbvie Inc
NYSE:ABBV
Cash Equivalents
$13.1B
CAGR 3-Years
15%
CAGR 5-Years
20%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Cash Equivalents
$2.8B
CAGR 3-Years
-17%
CAGR 5-Years
-24%
CAGR 10-Years
-11%
Amgen Inc
NASDAQ:AMGN
Cash Equivalents
$9.3B
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
8%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash Equivalents
$4.6B
CAGR 3-Years
-9%
CAGR 5-Years
7%
CAGR 10-Years
27%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash Equivalents
$1.9B
CAGR 3-Years
-2%
CAGR 5-Years
13%
CAGR 10-Years
12%

See Also

What is Intercept Pharmaceuticals Inc's Cash Equivalents?
Cash Equivalents
102.7m USD

Based on the financial report for Sep 30, 2023, Intercept Pharmaceuticals Inc's Cash Equivalents amounts to 102.7m USD.

What is Intercept Pharmaceuticals Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
12%

Over the last year, the Cash Equivalents growth was -9%. The average annual Cash Equivalents growth rates for Intercept Pharmaceuticals Inc have been 31% over the past three years , 12% over the past five years , and 12% over the past ten years .

Back to Top